Last updated on September 2018

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

Brief description of study

Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma patients, non-progressive after induction therapy.

Clinical Study Identifier: NCT02197221

Contact Investigators or Research Sites near you

Start Over


Centre Hospitalier de Mulhouse
Mulhouse, France